Ingrid Duijkers

No ORCID on file · 7 papers in corpus · active 2008-2018

Study types

  • article 7

Condition tags

  • endometriosis 1
article 2018
Effect on endometrial histology and pharmacokinetics of different dose regimens of progesterone vaginal pessaries, in comparison with progesterone vaginal gel and placebo
·doi:10.1093/humrep/dey288

STUDY QUESTION: Which progesterone vaginal pessary dose regimen induces adequate secretory transformation of the endometrium, in comparison with progesterone vaginal gel and placebo? SUMMARY ANSWER: The best secretory transformation of the …

article 2011
Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive
·doi:10.1007/bf03259805

Background: A novel estradiol-based combined oral contraceptive (COC) is currently available in many countries worldwide, including Europe and the US. Based on previous studies, it is expected that this estradiol-based COC will have a reduc…

article 2011
Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive
·doi:10.2165/11591200-000000000-00000

BACKGROUND: A novel estradiol-based combined oral contraceptive (COC) is currently available in many countries worldwide, including Europe and the US. Based on previous studies, it is expected that this estradiol-based COC will have a reduc…

article 2011
Ovulation‐Inhibiting Effects of Dienogest in a Randomized, Dose‐Controlled Pharmacodynamic Trial of Healthy Women
Journal of clinical pharmacology ·doi:10.1177/0091270011423664

Dienogest offers pharmacological advantages for the effective treatment of endometriosis and for use in contraception and hormone replacement therapy. This pharmacodynamic study investigated the ovulation-inhibiting effects of dienogest mon…

article 2010
Pharmacodynamic study of four oral dosages of dienogest
·doi:10.1016/j.fertnstert.2010.07.708
article 2008
Original research article Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies ☆,☆☆

Background: Attempts to improve the tolerability of combined oral contraceptives (COCs) have included the substitution of ethinylestradiol (EE) with 17β-estradiol (E2). However, this has proved unsatisfactory, specifically in terms of cycle…

article 2008
Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies
·doi:10.1016/j.contraception.2008.05.004

BackgroundAttempts to improve the tolerability of combined oral contraceptives (COCs) have included the substitution of ethinylestradiol (EE) with 17beta-estradiol (E2). However, this has proved unsatisfactory, specifically in terms of cycl…